Get Support
 / Kratom and 7-OH Use Disorder

How We Treat Kratom Use Disorder

What is Kratom and 7-Hydroxymitragynine (7-OH), and can you become addicted to them?

Yes. Kratom and its concentrated alkaloid derivatives, such as 7-hydroxymitragynine (7-OH), interact directly with mu-opioid receptors in the brain, leading to physical dependence, tolerance, and addiction.

While marketed as natural herbal supplements or energy boosters, raw kratom leaf and high-potency extracts contain active compounds (mitragynine and 7-hydroxymitragynine) that act as partial opioid agonists. Regular use leads to physiological dependence, causing severe opioid-like withdrawal symptoms when attempting to stop.

Product Type

Common Forms

Risk Level

Primary Biological Mechanism

Raw Kratom Leaf / Powder

Teas, raw powder, crushed leaf

Moderate to High Dependence

Contains raw mitragynine; acts as a partial mu-opioid agonist.

Concentrated Liquid Extracts

Shots, tincture bottles

High Dependence

Processed for higher alkaloid concentration and rapid absorption.

7-OH Concentrates / Tablets

Chewable tablets, synthetic extracts

Severe / Rapid Dependence

Highly potent isolated 7-hydroxymitragynine; strong mu-opioid affinity.

Evidence & Authoritative Reference:

The U.S. Food and Drug Administration (FDA) warns consumers that kratom exposes users to risks of addiction, abuse, and dependence, acting on the same brain receptors as conventional opioids (FDA Warning and Scientific Safety Data on Kratom).

Ideal Option treats Kratom Use Disorder using Medication-Assisted Treatment (MAT)—specifically buprenorphine-based medications (Suboxone®)—to safely replace unregulated alkaloids, eliminate cravings, and prevent withdrawal.

Because kratom alkaloids target the brain's opioid receptors, buprenorphine effectively binds to those same receptors with higher affinity. This stabilizes neurochemistry without producing euphoria, allowing patients to safely taper under medical supervision or transition to long-term recovery maintenance.

Treatment Phase

Primary Clinical Interventions

Objective

Evaluation & Intake

Clinical history, vitals, urine toxicology testing

Baseline health check and determination of alkaloid exposure.

Buprenorphine Induction

Low-dose Suboxone® sublingual film/tablet initiation

Rapid relief of kratom withdrawal symptoms and craving elimination.

Stabilization & Taper

Regular medical check-ins, medical dose adjustments

Gradual dose stabilization or structured medical taper tailored to individual goals.

Evidence & Authoritative Reference:

Research published by the National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA) demonstrates that buprenorphine is a safe and effective treatment for managing kratom withdrawal and supporting long-term recovery from severe kratom dependence (NIH/NIDA Research on Buprenorphine for Kratom Dependence).

No. You do not need to be in active, severe withdrawal to start treatment for Kratom or 7-OH dependence at Ideal Option.

Medical evaluations, urine toxicological panels, and vital sign checks are performed during your initial clinic visit. Addiction medicine providers evaluate your specific kratom formulation, daily dosage, and usage history to design a safe, comfortable transition plan that avoids severe withdrawal.

Commercial kratom products lack standardized dosing guidelines and are frequently contaminated with heavy metals, dangerous bacteria, or synthetic adulterants.

Key health risks include:

  • Lack of Dosage Regulation: Commercial extracts vary wildly in potency, making accidental over-consumption common.
  • Heavy Metal & Bacterial Contamination: Independent testing by federal health agencies has repeatedly identified lead, nickel, and Salmonella in retail kratom samples.
  • Polysubstance & Synthetic Adulteration: Illicit manufacturers may mix concentrated 7-OH products with synthetic opioids or sedative adulterants.

Evidence & Authoritative Reference: The Substance Abuse and Mental Health Services Administration (SAMHSA) highlights that the lack of quality controls in retail herbal supplements creates unpredictable health hazards, making medical supervision crucial for individuals seeking to stop use (SAMHSA Advisory on Emerging Substance Trends).

Researchers at Ideal Option presented the largest case series to date exploring long-term buprenorphine/naloxone treatment for kratom use disorder (KUD). After 12 weeks of treatment, 82% of participants had negative test results for mitragynine (kratom). To read the full article published in the Substance Abuse journal, click here: https://bit.ly/3GB6f5z. 

Get Started

You're just one step away from starting or restarting your recovery journey with Ideal Option. We've helped thousands of people get their lives back. Let's make yours one of them. 

Learn More